An update and future directions in advanced gastric or gastrointestinal junction cancer (G/GEJC)

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2022年 / 15卷 / SUPPL 6期
关键词：
OPEN-LABEL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：109 / 112
页数：4
相关论文
共 50 条
  • [21] Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer
    He, Puyi
    Ma, Long
    Xu, Bo
    Wang, Yunpeng
    Li, Xiaomei
    Chen, Hao
    Li, Yumin
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [22] Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience
    Soini, Barbara
    Pani, Giuseppe
    Caffo, Orazio
    Frisinghelli, Michela
    Veccia, Antonello
    Brugnara, Sonia
    Caldara, Alessia
    DiPasquale, MariaChiara
    Ferro, Antonella
    Mussari, Salvatore
    Murgia, Viviana
    Russo, Lucianna
    Valduga, Francesco
    Tumulo, Salvatore
    Galligioni, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Immunotherapy in advanced gastric cancer, is it the future?
    Coutzac, C.
    Pernot, S.
    Chaput, N.
    Zaanan, A.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 133 : 25 - 32
  • [24] Economic evaluation of trifluridine/tipiracil (TT) versus nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastro-esophageal junction cancer (GEJC) in Canada
    Virik, Kiran
    Wilson, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.
    Kelly, Ronan Joseph
    Le, Hannah
    Wu, Sze-Jung
    Laurie, Melissa
    Raval, Amit D.
    Shi, Qian
    Korytowsky, Beata
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
    Hall, J.
    Khela, K.
    Bertwistle, D.
    Xiao, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S482 - S483
  • [27] Clinical outcome of pembrolizumab in clinical studies for advanced gastric and gastroesophageal junction (G/GEJ) cancer
    Muro, Kei
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 35 - 35
  • [28] State of the art treatment for gastric cancer: future directions
    Cervantes, A
    Georgoulias, V
    Falcone, A
    [J]. EJC SUPPLEMENTS, 2004, 2 (07): : 40 - 47
  • [29] Adjuvant therapy for gastric cancer:Current and future directions
    Marcus Foo
    Trevor Leong
    [J]. World Journal of Gastroenterology, 2014, (38) : 13718 - 13727
  • [30] Adjuvant therapy for gastric cancer: Current and future directions
    Foo, Marcus
    Leong, Trevor
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (38) : 13718 - 13727
12345